|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
2000-4-13
|
|
pubmed:abstractText |
In immunocompetent mice with candidiasis, successful therapy with amphotericin B and fluconazole relies on the induction of protective, T helper (Th) type 1 responses, an effect potentiated by concomitant interleukin (IL)-4 neutralization. To assess the therapeutic efficacy of combined treatments with antifungals and immunomodulators in conditions of immunosuppression, leukopenic or neutropenic mice with disseminated candidiasis were treated with amphotericin B or fluconazole alone or in combination with soluble IL-4 receptor (sIL-4R) or recombinant (r) IL-12 or IL-10 neutralizing monoclonal antibodies. We found that (1) the synergistic effect of sIL-4R and antifungals is retained in immunocompromised mice; (2) synergism with amphotericin B was superior to that with fluconazole, particularly in leukopenic mice; (3) rIL-12 synergized with fluconazole in neutropenic mice; and (4) IL-10 neutralization was always of limited efficacy. This study indicates that the therapeutic efficacy of antifungals is differentially potentiated by cytokines or cytokine antagonists and is influenced by host immune reactivity.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Amphotericin B,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal,
http://linkedlifedata.com/resource/pubmed/chemical/Antifungal Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Cytokines,
http://linkedlifedata.com/resource/pubmed/chemical/Fluconazole,
http://linkedlifedata.com/resource/pubmed/chemical/Interleukin-10,
http://linkedlifedata.com/resource/pubmed/chemical/Interleukin-12,
http://linkedlifedata.com/resource/pubmed/chemical/RNA, Messenger,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Interleukin-4,
http://linkedlifedata.com/resource/pubmed/chemical/Recombinant Proteins
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
0022-1899
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
181
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
686-94
|
|
pubmed:dateRevised |
2009-11-19
|
|
pubmed:meshHeading |
pubmed-meshheading:10669356-Amphotericin B,
pubmed-meshheading:10669356-Animals,
pubmed-meshheading:10669356-Antibodies, Monoclonal,
pubmed-meshheading:10669356-Antifungal Agents,
pubmed-meshheading:10669356-Candida albicans,
pubmed-meshheading:10669356-Candidiasis,
pubmed-meshheading:10669356-Combined Modality Therapy,
pubmed-meshheading:10669356-Cytokines,
pubmed-meshheading:10669356-Female,
pubmed-meshheading:10669356-Fluconazole,
pubmed-meshheading:10669356-Humans,
pubmed-meshheading:10669356-Immunocompromised Host,
pubmed-meshheading:10669356-Immunotherapy,
pubmed-meshheading:10669356-Interleukin-10,
pubmed-meshheading:10669356-Interleukin-12,
pubmed-meshheading:10669356-Kidney,
pubmed-meshheading:10669356-Mice,
pubmed-meshheading:10669356-Mice, Inbred BALB C,
pubmed-meshheading:10669356-RNA, Messenger,
pubmed-meshheading:10669356-Receptors, Interleukin-4,
pubmed-meshheading:10669356-Recombinant Proteins,
pubmed-meshheading:10669356-Th1 Cells
|
|
pubmed:year |
2000
|
|
pubmed:articleTitle |
Host immune reactivity determines the efficacy of combination immunotherapy and antifungal chemotherapy in candidiasis.
|
|
pubmed:affiliation |
Microbiology Section, Department of Experimental Medicine and Biochemical Sciences, University of Perugia, 06122 Perugia, Italy.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
